News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s New Once-daily HIV Drug Matches Merck & Co., Inc. (MRK) Rival


4/2/2012 7:37:27 AM

A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug dolutegravir and Isentress are so-called integrase inhibitors, a novel class of drugs for fighting HIV/AIDS that block the virus causing the disease from entering cells. Dolutegravir is important for GSK since it could help rejuvenate its HIV/AIDS business - an area of medicine it used to dominate but where it has fallen behind rivals in recent years.

Read at Fox News
Read at News Release


comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES